Email Alert | RSS

Journal of Peking University(Health Sciences) ›› 2018, Vol. 50 ›› Issue (6): 1014-1021. doi: 10.19723/j.issn.1671-167X.2018.06.013

• Article • Previous Articles     Next Articles

Efficacy of mesenchymal stem cells on systemic lupus erythematosus:a meta-analysis

Shuang LIU1,Yu-long GUO2,Jing-yi YANG3,Wei WANG1,Jian XU1,△()   

  1. 1. Department of Rheumatology and Immunology, First Affiliated Hospital of Kunming Medical University, Kunming 650032, China
    2. Department of Cardiology, Yunnan Provincial Fuwai Cardiovascular Disease Hospital, Kunming 650000, China
    3. Yunnan Shunxi Regeneration Medical Engineering Co., Ltd, Kunming 650000, China
  • Received:2018-07-10 Online:2018-12-18 Published:2018-12-18
  • Contact: Jian XU E-mail:casxujian@163.com
  • Supported by:
    Supported by the National Natural Science Foundation of China(81160379);Supported by the National Natural Science Foundation of China(81460256);Supported by the National Natural Science Foundation of China(81560233);Supported by the National Natural Science Foundation of China(81501406);Supported by the National Natural Science Foundation of China(81760296);Yunnan Applied Basic Research Projects-Union Foundation(2017FE467);Yunnan Applied Basic Research Projects-Union Foundation(2017FE467(-138));the Funding of Yunnan Provincial Health Science and Technology Plan(2014NS171);the Funding of Yunnan Provincial Health Science and Technology Plan(2016NS026);the Funding of Yunnan Provincial Health Science and Technology Plan(2016NS052);the Funding of Yunnan Provincial Health Science and Technology Plan(2017NS051);the Funding of Yunnan Provincial Health Science and Technology Plan(2018NS0133);the Funding of Yunnan Provincial Health Science and Technology Plan(2018NS0134);Yunnan Provincial Fund for High Level Reserve Talents in Health Science(H-2017068);Yunnan Provincial Fund for Preparatory Young Leaders in Academic and Technology(2015HB071);Yunnan Provincial Fund for Preparatory Young Leaders in Academic and Technology (2015HB071), the Hundred-Talent Program of Kunming Medical University(60117190457);Innovative Research Team of Kunming Medical University(CXTD201613)

RICH HTML

   

PDF (PC)

Abstract:

Objective: Systemic lupus erythematosus (SLE) is an autoimmune disease with multi-organ involvement and several typical autoantibodies. Mesenchymal stem cells (MSC) are multipotent stem cells with low immunogenicity that can differentiate into various kinds of cells, such as bone, cartilage, fat and skin tissue. MSC have immunomodulatory and reparative properties through interactions with immune cells. MSC have been used in the treatment of refractory SLE and lupus nephritis patients for more than ten years. Most clinical studies were self-controlled studies and only a few were randomized controlled trials. The objective of this study was to use meta-analysis method to evaluate the efficacy and safety of MSC treatment in SLE patients. Methods:The PubMed, Cochrane Library, Wanfang and VIP databases were searched for published randomized controlled trials and self-controlled studies before June 1, 2018. The search terms included the Chinese and English versions of mesenchymal stem cells, Mesenchymal Stromal Cells [Mesh], systemic lupus erythematosus, lupus, Lupus Erythematosus, Systemic [Mesh]. Two authors independently screened the literatures, assessed the quality of the studies and collected data according to the inclusion and exclusion criteria. The endpoints were the SLE disease activity index, 24 h urine protein and complement C3. Meta-analysis was performed with the Revman 5.3 software according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standard. Results:Eight studies involving 213 patients were included and three of the studies were randomized controlled trials with 66 patients involved. The MSC group showed that the SLE disease activity index decreased significantly [standard mean difference (SMD)=-1.76, 95% confidence interval (CI):-2.00 to -1.51, P<0.001), the 24 h urine protein decreased significantly (SMD=-1.74, 95%CI:-2.46 to -1.03, P<0.001), as well as the complement C3 increased significantly (SMD=1.28, 95%CI: 0.93 to 1.62, P<0.001). Four studies reported adverse events including fever, diarrhea and headache during the infusion. Conclusion:Current evidences showed that MSC could improve the disease activity, proteinuria and hypocomplementemia in SLE patients. Large scale and high-quality randomized controlled trials are required to validate the efficacy and safety of MSC treatment in SLE patients.

Key words: Mesenchymal stem cell, Systemic lupus erythematosus, Lupus nephritis, Meta-analysis

CLC Number: 

  • R593.24

Figure 1

Flow of study selection"

Table 1

Table A summary of the included eight studies"

Table 2

Quality assessment of randomized controlled trials"

Table 3

Quality assessment of self-control studies"

Study Representativeness of the exposed cohort Selection
of the non-
exposed cohort		 Ascertainment of
exposure		 Demonstration that the outcome of
interest was
not present
at baseline		 Comparability of cohorts on the basis of design or analysis Assessment of the out-
come		 Was follow-up enough
for outcomes
to occur?		 Adequacy of
follow-up of
cohorts
Gu, et al, 2014[15] Yes NA Yes Yes NA Yes Yes Yes
Zhu, et al, 2016[17] Yes NA Yes Yes NA Yes No Yes
Li, et al, 2016[13] Yes NA Yes Yes NA Yes Yes Yes
Qiu, et al, 2016[18] Yes NA Yes Yes NA Yes Yes Yes
Bai, et al, 2017[12] Yes NA Yes Yes NA Yes Yes Yes

Figure 2

Summary of meta-analysis for SLEDAI outcomesRCT, randomized controlled trial;SD, standard deviation;CI, confidence interval;SLEDAI, systemic lupus erythematosus disease activity index."

Figure 3

Summary of meta-analysis for urine protein outcomesAbbreviations as in Figure 2."

Figure 4

Summary of meta-analysis for complement outcomesAbbreviations as in Figure 2."

[1] 中华医学会风湿病学分会. 系统性红斑狼疮诊断及治疗指南[J]. 中华风湿病学杂志, 2010,14(5):342-346.
[2] van Vollenhoven RF, Mosca M, Bertsias G , et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force[J]. Ann Rheum Dis, 2014,73(6):958-967.
doi: 10.1136/annrheumdis-2013-205139 pmid: 24739325
[3] He J, Zhang X, Wei Y , et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus[J]. Nat Med, 2016,22(9):991-993.
doi: 10.1038/nm.4148 pmid: 27500725
[4] 王丹丹, 孙凌云 . 间充质干细胞移植治疗重症自身免疫病[J]. 中国实用内科杂志, 2015,35(10):831-834.
[5] 梁军, 孙凌云 . 间充质干细胞治疗系统性红斑狼疮的基础和临床研究[J]. 浙江医学, 2017,39(21):1836-1841.
[6] Carrion F, Nova E, Ruiz C , et al. Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupuserythematosus patients[J]. Lupus, 2010,19(3):317-322.
doi: 10.1177/0961203309348983
[7] Deng D, Zhang P, Guo Y , et al. A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis[J]. Ann RheumDis, 2017,76(8):1436-1439.
doi: 10.1136/annrheumdis-2017-211073
[8] Hochberg MC . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus[J]. Arthritis Rheum, 1997,40(9):1725.
[9] Petri M, Orbai A, Alarcón GS , et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus[J]. Arthritis Rheum, 2012,64(8):2677-2686.
doi: 10.1002/art.34473
[10] Gladman DD, Iba ED, Urowitz MB . Systemic lupus erythematosus disease activity index 2000[J]. J Rheumatol, 2002,29(2):288-291.
doi: 10.1097/00124743-200202000-00018 pmid: 11838846
[11] 杨桂鲜, 潘丽萍, 陈志琴 , 等. 脐带间充质干细胞移植治疗狼疮性肾炎的临床疗效[J]. 实用医学杂志, 2014,30(17):2779-2781.
doi: 10.3969/j.issn.1006-5725.2014.17.029
[12] 白茹, 戚燕, 吕昭萍 , 等. 脐带间充质干细胞移植治疗难治性系统性红斑狼疮3年随访[J]. 中国免疫学杂志, 2017,33(6):905-909.
doi: 10.3969/j.issn.1000-484X.2017.06.020
[13] 李俊霞, 林强, 陈建 , 等. 脐带间充质干细胞对增殖型狼疮性肾炎的临床疗效观察[J]. 中华细胞与干细胞杂志: 电子版, 2016,6(3):174-178.
doi: 10.3877/cma.j.issn.2095-1221.2016.03.007
[14] 唐帮丽, 邓丹琪, 张佩莲 , 等. 脐带间充质干细胞移植治疗狼疮性肾炎的疗效与机制[J]. 昆明医科大学学报, 2016,37(7):93-98.
doi: 10.3969/j.issn.1003-4706.2016.07.022
[15] Gu F, Wang D, Zhang H , et al. Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy[J]. Clin Rheumatol, 2014,33(11):1611-1619.
doi: 10.1007/s10067-014-2754-4 pmid: 25119864
[16] 曾雯, 胡英, 杨霞 , 等. 间充质干细胞联合吗替麦考酚酯治疗狼疮性肾炎的临床效果[J]. 中国当代医药, 2016,23(7):67-70.
[17] 朱宁, 毛静, 张小莲 , 等. 脐带间充质干细胞移植在系统性红斑狼疮患者中的应用研究[J]. 疑难病杂志, 2016,15(1):44-47.
doi: 10.3969/j.issn.1671-6450.2016.01.011
[18] 裘影影, 何建强, 汤郁 , 等. 脐带间充质干细胞移植治疗难治性系统性红斑狼疮患者的疗效分析[J]. 中国实用医药, 2016,11(25):68-69.
[19] Sun L, Akiyama K, Zhang H , et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans[J]. Stem Cells, 2009,27(6):1421-1432.
doi: 10.1002/stem.68 pmid: 19489103
[20] 杨桂鲜, 潘丽萍, 曹礼应 , 等. 脐带间充质干细胞治疗难治性系统性红斑狼疮的临床研究[J]. 云南医药, 2018,39(1):38-41.
[21] 杨桂鲜, 潘丽萍, 陈志琴 , 等. 脐带间充质干细胞治疗系统性红斑狼疮的量效关系[J]. 云南医药, 2015,36(6):579-584.
[22] 杨桂鲜, 潘丽萍, 宋薇 , 等. 脐带间充质干细胞治疗难治性系统性红斑狼疮临床分析[J]. 实用医学杂志, 2014,30(5):735-738.
doi: 10.3969/j.issn.1006-5725.2014.05.019
[23] 杨桂鲜, 潘丽萍, 周巧艳 , 等. 脐带间充质干细胞移植辅助治疗系统性红斑狼疮的疗效观察[J]. 四川大学学报(医学版), 2014,45(2):338-341.
[24] Klimczak A, Kozlowska U . Mesenchymal stromal cells and tissue-specific progenitor cells: their role in tissue homeostasis[J]. Stem Cells Int, 2016,4285215. doi: 10.1155/2016/4285215.
doi: 10.1155/2016/4285215 pmid: 4707334
[25] Sun LY, Zhang HY, Feng XB , et al. Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus[J]. Lupus, 2007,16(2):121-128.
doi: 10.1177/0961203306075793
[26] Nie Y, Lau C, Lie A , et al. Defective phenotype of mesenchymal stem cells in patients with systemic lupus erythematosus[J]. Lupus, 2010,19(7):850-859.
doi: 10.1177/0961203310361482 pmid: 20118163
[27] Li X, Liu L, Meng D , et al. Enhanced apoptosis and senescence of bone-marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus[J]. Stem Cells Dev, 2012,21(13):2387-2394.
doi: 10.1089/scd.2011.0447 pmid: 22375903
[28] Gu Z, Tan W, Feng G , et al. Wnt/beta-catenin signaling me-diates the senescence of bone marrow-mesenchymal stem cells from systemic lupus erythematosus patients through the p53/p21 pathway[J]. Mol Cell Biochem, 2014,387(1-2):27-37.
doi: 10.1007/s11010-013-1866-5 pmid: 24130040
[29] Wang D, Feng X, Lu L , et al. A CD8 T cell/indoleamine 2, 3-dioxygenase axis is required for mesenchymal stem cell suppression of human systemic lupus erythematosus[J]. Arthritis Rheum, 2014,66(8):2234-2245.
doi: 10.1002/art.38674 pmid: 24756936
[30] Feng X, Che N, Liu Y , et al. Restored immunosuppressive effect of mesenchymal stem cells on B cells after olfactory 1/early B cell factor-associated zinc-finger protein down-regulation in patients with systemic lupus erythematosus[J]. Arthritis Rheum, 2014,66(12):3413-3423.
doi: 10.1002/art.v66.12
[31] Fathollahi A, Gabalou NB, Aslani S . Mesenchymal stem cell transplantation in systemic lupus erythematous, a mesenchymal stem cell disorder[J]. Lupus, 2018,27(7):1053-1064.
doi: 10.1177/0961203318768889
[32] Choi EW, Shin IS, Park SY , et al. Reversal of serologic, immunologic, and histologic dysfunction in mice with systemic lupus erythematosus by long-term serial adipose tissue-derived mesenchymal stem cell transplantation[J]. Arthritis Rheum, 2012,64(1):243-253.
doi: 10.1002/art.33313 pmid: 21904997
[33] Choi EW, Lee M, Song JW , et al. Mesenchymal stem cell transplantation can restore lupus disease-associated miRNA expression and Th1/Th2 ratios in a murine model of SLE[J]. Sci Rep, 2016(6):38237.
doi: 10.1038/srep38237 pmid: 27924862
[34] Zhou K, Zhang H, Jin O , et al. Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice[J]. Cell Mol Immunol, 2008,5(6):417-424.
doi: 10.1038/cmi.2008.52
[35] Tang Y, Xie H, Chen J , et al. Activated NF-kappaB in bone marrow mesenchymal stem cells from systemic lupus erythematosus patients inhibits osteogenic differentiation through downregulating Smad signaling[J]. Stem Cells Dev, 2013,22(4):668-678.
doi: 10.1089/scd.2012.0226
[36] Sun L, Wang D, Liang J , et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus[J]. Arthritis Rheum, 2010,62(8):2467-2475.
doi: 10.1002/art.v62:8
[37] Zhang Z, Feng R, Niu L , et al. Humanumbilical cord mesenchymal stem cells inhibit T follicular helper cell expansion through the activation of iNOS in lupus-prone B6.MRL-Fas(lpr) mice[J]. Cell Transplant, 2017,26(6):1031-1042.
doi: 10.3727/096368917X694660 pmid: 28105982
[38] Deng W, Chen W, Zhang Z , et al. Mesenchymal stem cells promote CD206 expression and phagocytic activity of macrophages through IL-6 in systemic lupus erythematosus[J]. Clin Immunol, 2015,161(2):209-216.
doi: 10.1016/j.clim.2015.07.011 pmid: 26209923
[39] Che N, Li X, Zhou S , et al. Umbilical cord mesenchymal stem cells suppress B-cell proliferation and differentiation[J]. Cell Immunol, 2012,274(1-2):46-53.
doi: 10.1016/j.cellimm.2012.02.004 pmid: 22414555
[40] Le Blanc K, Ringden O . Immunomodulation by mesenchymal stem cells andclinical experience[J]. J Intern Med, 2007,262(5):509-525.
doi: 10.1016/j.placenta.2011.07.035 pmid: 17949362
[41] Chamberlain G, Fox J, Ashton B , et al. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing[J]. Stem Cells, 2007,25(11):2739-2749.
doi: 10.1634/stemcells.2007-0197
[42] Alunno A, Bistoni O, Montanucci P , et al. Umbilical cord mesenchymal stem cells for the treatment of autoimmune diseases: beware of cell-to-cell contact[J]. Ann RheumDis, 2018,77(3):e14.
doi: 10.1136/annrheumdis-2017-211790 pmid: 28611081
[43] Lalu MM, Mcintyre L, Pugliese C , et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials[J]. PLoS One, 2012,7(10):e47559.
doi: 10.1371/journal.pone.0047559
[44] 汤郁, 雷芳, 宋东明 , 等. 脐带间充质干细胞治疗结缔组织病不良反应分析[J]. 南京医科大学学报(自然科学版), 2014,34(12):1687-1689.
[1] Han ZHANG, Fujia YANG, Ruili YANG. Progress in regulating stem cell functions for repair and regeneration of craniomaxillofacial tissues [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 285-289.
[2] Xiaofei TANG, Qiuling DING, Yang ZHANG, Yumei WANG, Meiyi TIAN, Zhuo SUN, Rongrong WANG, Yan CHEN, Jian LIU. Refractory systemic lupus erythematosus-associated thrombocytopenia treated with avatrombopag: A case report [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 405-409.
[3] Liting ZENG, Kaiyuan CHENG, Zhongning LIU, Jian LI, Jingwen YANG, Ting JIANG. miR-488-5p promotes osteogenic and neurogenic differentiation of rat bone marrow mesenchymal stem cells and enhances neuralized bone regeneration [J]. Journal of Peking University (Health Sciences), 2026, 58(1): 10-21.
[4] Xinyi LI, Jinxia ZHAO, Rong MU. Impact of aspirin use on pregnancy outcomes in patients with systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1074-1080.
[5] Xiaolin WANG, Shaoyi GUO, Dazhao CHEN, Xijie WEN, Yong HUA, Liang ZHANG, Qin ZHANG. A follow-up study on total hip arthroplasty in patients with systemic lupus erythematosus combined with osteonecrosis of femoral head [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1081-1088.
[6] Chun WEI, Yue YANG, Xinju ZHAO, Xu LIU, Yuan JIA. Systemic lupus erythematosus complicated by autoimmune nodopathy: A case report [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1174-1179.
[7] Kai ZHAO, Fu'ai LU, Yongfu WANG. Central nervous system infection mimicking neuropsychiatric systemic lupus erythematosus: A case report [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1188-1192.
[8] Wenqiong WANG, Yuke HOU, Chun LI, Xuewu ZHANG. Predictors of adverse pregnancy outcomes in patients with systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2025, 57(3): 599-603.
[9] Chunhui SHENG, Xiao ZHANG, Longwei LV, Yongsheng ZHOU. Exosome derived from human adipose-derived mesenchymal stem cells prevented bone loss induced by estrogen deficiency [J]. Journal of Peking University (Health Sciences), 2025, 57(2): 217-226.
[10] Ting SHUAI, Yanyan GUO, Chunping LIN, Xiaomei HOU, Chanyuan JIN. Knockdown of NPTX1 promotes osteogenic differentiation of human bone marrow mesenchymal stem cells [J]. Journal of Peking University (Health Sciences), 2025, 57(1): 7-12.
[11] Hongyan WANG, Xinming LI, Kechi FANG, Huaqun ZHU, Rulin JIA, Jing WANG. Analysis of characteristics related to the disease activity of systemic lupus erythematosus and construction of an evaluation model [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1017-1022.
[12] Dandan CHEN, Yun LI, Qingyi LU, Xiaohong XIANG, Feng SUN, Yingni LI, Jing ZHAO, Hongyan WANG, Chun LI. Ovarian function in patients of childbearing age with systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1023-1028.
[13] Li WANG, Chao GAO, Huanhuan REN, Yanping SHEN, Xiaowei HUANG, Hong YAO, Dandan HAN. Current status and influential factors of self-management ability in patients with systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1029-1035.
[14] Jing CHAI, Yue WANG, Rong MU, Jinxia ZHAO. Systemic lupus erythematosus involving the fornix column leading to hyponatremia: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1115-1118.
[15] Mingxia WANG, Ling DING, Min WANG, Chanjuan ZOU, Siyu YAN, Yingwen LIANG, Weijia WANG, Shanzhi HE. Safe pregnancy and delivery in a female patient with systemic lupus erythematosus after discontinuation of dual-target chimeric antigen receptor T cells therapy [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1119-1125.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd